Lower Respiratory Tract Disease caused by Respiratory Syncytial Virus (RSV)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB16258 | Nirsevimab | A long-acting monoclonal antibody indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. |
| DB18713 | Recombinant stabilized RSV A prefusion F antigen | One component of a bivalent recombinant RSV vaccine. |
| DB18714 | Recombinant stabilized RSV B prefusion F antigen | One component of a bivalent recombinant RSV vaccine. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB16258 | Nirsevimab | Fusion glycoprotein F0 | target |
| DB16258 | Nirsevimab | Fusion glycoprotein F0 | target |
| DB16258 | Nirsevimab | Fusion glycoprotein F0 | target |
| Drug | Drug Name | Phase | Status | Count |
|---|